Drake LA, Scher RK, Smith EB, et al: Effect of onychomycosis on quality of life. .J Am Acad Dermatol 38::702. ,1998. .
Scher RK: Onychomycosis: a significant medical disorder. .J Am Acad Dermatol 35::S2. ,1996. .
Scher RK: Onychomycosis is more than a cosmetic problem. .Br J Dermatol 130: (suppl 43):15. ,1994. .
Rich P, Schein JR, Lubeck D: Onychomycosis: symptoms and quality of life associated with this medical condition [poster]. Presented at a meeting of the American Academy of Dermatology, July 31–August 4, 1998, Chicago..
Lubeck DP, Gause D, Schein JR, et al: A health-related quality of life measure for use in patients with onychomycosis: a validation study. .Qual Life Res 8::121. ,1999. .
Drake L: Quality of life issues for patients with fungal nail infections. .AIDS Patient Care 9: (suppl 1):S15. ,1995. .
Lubeck DP: Measuring health-related quality of life in onychomycosis. .J Am Acad Dermatol 38::S64. ,1998. .
Elewski BE: Onychomycosis: pathogenesis, diagnosis, and management. .Clin Microbiol Rev 11::415. ,1998. .
Cohen PR, Scher RK: Topical and surgical treatment of onychomycosis. .J Am Acad Dermatol 31::S74. ,1994. .
Arenas R, Domínguez-Cherit J, FernÁndez LM: Open randomized comparison of itraconazole versus terbinafine in onychomycosis. .Int J Dermatol 34::138. ,1995. .
BrÄutigam M, Nolting S, Schopf RE, et al: Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. .BMJ 311::919. ,1995. .
DiMatteo MR: Patient adherence to pharmacotherapy: the importance of effective communication. .Formulary 30::596. ,1995. .
Hiruma M, Matsushita A, Kobayashi M, et al: One week pulse therapy with itraconazole (200 mg day-1) for onychomycosis: evaluation of treatment results according to patient background. .Mycoses 44::87. ,2001. .
Gupta AK, De Doncker P, Haneke E: Itraconazole pulse therapy for the treatment of Candida onychomycosis. .J Eur Acad Dermatol Venereol 15::112. ,2000. .
Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. .Med Care 24::67. ,1986. .
Lohr KN, Aaronson NK, Alonso J, et al: Evaluating quality-of-life and health status instruments: development of scientific review criteria. .Clin Ther 18::979. ,1996. .
Cronbach LJ: Coefficient alpha and the internal structure of tests. .Psychometrika 16::297. ,1951. .
Sporanox [package insert], Janssen Pharmaceutica, Inc, Titusville, NJ, 2001..
Lamisil [package insert], Novartis Pharmaceuticals Corp, East Hanover, NJ, 2001..
The purpose of this study, which involved two dermatology clinics and two podiatric medical clinics, was to determine whether a difference exists in patient-reported satisfaction and compliance between continuous terbinafine therapy and pulse-dose itraconazole therapy for the treatment of toenail onychomycosis. Patients in this multicenter, open-label, cross-sectional study had previously completed treatment with either oral terbinafine or oral itraconazole for toenail onychomycosis. Patients were interviewed by telephone to assess clinical outcomes, compliance, and satisfaction with treatment; clinical data were collected by medical chart review. Patients reported significantly greater ease and convenience of treatment and higher overall satisfaction with continuous terbinafine therapy compared with pulse-dose itraconazole therapy. (J Am Podiatr Med Assoc 93(5): 373-379, 2003)